Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Researchers Awarded Almost £1 Million to Target High Blood Pressure

Published: Tuesday, August 21, 2012
Last Updated: Tuesday, August 21, 2012
Bookmark and Share
Study shows that reduced blood flow to the brain will trigger high blood pressure.

University of Bristol researchers have received funding of almost £1 million from the British Heart Foundation to provide novel therapeutic targets for the treatment of high blood pressure.

Affecting one in three people, the treatment of patients with high blood pressure has important clinical and financial implications for public health.

Although scientists know what factors can trigger high blood pressure many of the mechanisms that regulate the long-term control of blood pressure remain a mystery.

Scientists from the University’s School of Physiology and Pharmacology, who are leading the five-year study, believe that these underlying mechanisms are triggered by poor blood delivery to the brain which responds by pushing blood pressure up causing high blood pressure.

This process re-directs blood into the brain to restore adequate flow. In previous studies, involving patient and an animal model of human hypertension, the blood vessels supplying the brain with blood are narrow and resistant to flow.

They also fail to dilate when brain activity increases, which is a time when more blood flow is needed to deliver oxygen and nutrients. So, there appears a greater susceptibility for stroke in high blood pressure.

The study aims to provide new evidence that shows reduced blood flow to the brain will trigger high blood pressure and provide novel therapeutic targets for the treatment of high blood pressure.

Professor Julian Paton, the study’s lead scientist, said: “You have to consider the brain as the most selfish organ in the body; if it is not satiated with enough blood flow it is the most powerful organ in the body for ramping up the pressure.

“We are absolutely delighted to have been given this award from the British Heart Foundation as it directs much needed attention to the brain and provides the opportunity to come up with new ways to control blood pressure in patients that are devoid of the awful side effects of so many currently prescribed drugs.”

Professor Sergey Kasparov, co-investigator on the study added: “We will attempt to prevent the narrowing of brain arteries in high blood pressure so to improve blood flow, unearth the intra-cranial sensors that detect low brain blood flow that trigger high blood pressure and find out why brain vessels are reluctant to dilate when brain activity increases.”

Dr Hélène Wilson, Research Advisor at the British Heart Foundation (BHF), said: “We’re delighted to award almost £1 million to this Bristol team for their work on understanding the causes of high blood pressure, which can lead to greater risk of having a heart attack or stroke. This latest project is looking at a possible role for the brain in effective blood pressure control, and is part of a wide research programme that we hope will help lead us towards new treatments in the future."

The study, entitled ‘Brainstem hypoperfusion as a causative mechanism for neurogenic hypertension’ led by Professor Julian Paton at the University of Bristol, is funded by a British Heart Foundation grant of £980,415.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Findings Could Influence the Development of Therapies to Treat Dengue Disease
New research into the fight against Dengue may influence the development of anti-viral therapies that are effective against all four types of the virus.
Monday, August 05, 2013
Alzheimer’s to Benefit from Landmark MRC-AstraZeneca Compound Collaboration
A study to investigate Alzheimer’s disease led by scientists at the University of Bristol has been awarded funding by the Medical Research Council (MRC).
Tuesday, November 06, 2012
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos